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INTRODUCTION
Ovarian cancer is the most cause of death among
gynecological cancer in the western countries1, and
is the second most cancer prevalence after cervical
cancer. In the last 10 years the incidence of this
disease increase about 30 %, lead to mortality in-
creased of 18 %2. The incidence of ovarian cancer
is 15 cases per 100,000 women every year and
141,000 new cases found with 106,000 death cases
every year around the world3. In United States,
25,400 new cases of ovarian cancer in 2003, which
14,300 among those was death2.
The incidence of ovarian cancer is increase at
every age increasing of a woman, from 15.7 in
100,000 women at 40 years old, to 54 in 100,000
women at 79 years old2. Overall, it could be state
that 1 of 70 women will have ovarian cancer in her
life.
The hypothesis about ovarian cancer pathogene-
sis is still unclear and need further investigation.
Until now, the hypothesis about ovarian cancer pa-
thogenesis include inclusion bodies formation lead
to malignant transformation in ovary’s stroma4, in-
cessant ovulation5, androgen and progesterone hor-
mones influence6,7,8. Some risk factors of ovarian
cancer have been identified, including parity, oral
contraception, and ovulation induction drugs. How-
ever, these factors still need further study. The ob-
stacle in ovarian cancer research is that of this dis-
ease is diagnosed at advance stage because no signs
and symptoms at early stage, also the location is
more hiding compare to other reproduction or-
gans5.
The morbidity and mortality rates of ovarian can-
cer are still high in the last 3 decades, because the
etiology and pathogenesis of this disease is still un-
clear. One of the reason is limitation of molecular
biology underlie this disease and limitation of
biomarker for detection.
p53 gene is the most study gene in the prognosis
and chemotherapy response prediction of ovarian
Tujuan: Mengetahui peranan gen p53 dan mengidentifikasi nilai
prognostik ekspresi protein p53 mutan terhadap kanker ovarium.
Rancangan/rumusan data: Penelitian survei analitik dengan desain
cross sectional pada rumah sakit pendidikan di Makassar.
Bahan dan cara kerja: Pasien dinyatakan kanker ovarium berda-
sarkan hasil pemeriksaan histopatologi, dianalisis ekspresi protein p53-
nya dengan teknik imunohistokimia.
Hasil: Derajat ekspresi protein p53 ditemukan lebih tinggi pada
kanker ovarium stadium lanjut. Follow-up penderita antara 6 bulan sam-
pai 2 tahun setelah operasi menunjukkan bahwa penderita yang mem-
punyai ekspresi protein p53 mutan yang tinggi mempunyai angka ke-
matian yang tinggi.
Kesimpulan: Analisis p53 dapat dipakai sebagai indikator prog-
nostik terhadap kanker ovarium.
[Maj Obstet Ginekol Indones 2008; 32-3: 172-6]
Kata kunci: p53, kanker ovarium, prognosis.
Objective: To investigate the role of p53 gene and to identify prog-
nostic value of p53 mutant expression in ovarian cancer
Design/data identification: Analytical survey with cross sectional
approach in institutional hospitals in Makassar.
Material and methods: The immunohistochemical of p53 expres-
sion analysis of ovarian cancer were performed. All samples have been
diagnosed by histopathological examination.
Results: The p53 overexpression was found in the advance stage of
ovarian cancer. Follow-up of patients for 6 months - 2 years after the
operation showed that the higher p53 overexpression, the higher mor-
tality.
Conclusion: p53 analysis can be used as a prognostic indicator of
ovarian cancer.
[Indones J Obstet Gynecol 2008; 32-3: 172-6]
Keywords: p53, ovarian cancer, prognosis.
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cancer patients. It has been demonstrated that mu-
tation and accumulation of p53 can be used as che-
mosensitivity prediction of ovarian cancer, which
mutation and expression of p53 proteins were in-
creased after chemotherapy9. This results demons-
trated that apoptosis by p53 gene was related to
ovarian cancer chemosensitivity.
In this study, we perform the analysis of p53
overexpression in ovarian cancer tissues. The p53
gene is known to play a role in cell survival and
that makes it interesting to study the role of this
gene in ovarian cancer pathogenesis since the in-
cidence, morbidity, and mortality rates of ovarian
cancer is high in Indonesia. The knowledge of ovar-
ian cancer pathogenesis lead to prompt treatment
to the patients includes chemotherapy.
This study also analyzed the role of p53 gene in
the prognosis of ovarian cancer. This issue is im-
portant in antiresistant drugs development, since the
resistant of ovarian cancer chemotherapy is still
high. Furthermore, molecular study of ovarian can-
cer in Indonesia is still limited and this study could
gain the development of basic research for clinical
applications.
MATERIALS AND METHODS
This study was an analitical survey using cross sec-
tional study. The research location was at Teaching
Hospital Dr Wahidin Sudirohusodo Faculty of
Medicine Hasanuddin University Makassar bet-
ween 2003 - 2005. Samples were patient suspected
ovarian cancer patients by clinical examinations, ul-
trasound, Doppler trans-abdominal/vaginal, and
CA-125 tumor marker examinations. Disease stages
were determined using FIGO 2000 criteria. Ovarian
cancer diagnosis was established by histopatholo-
gical examinations.
Samples were obtained from 41 malignant ovar-
ian tumor. None of patients received therapy before
surgery, and all patients had been followed up to
have the survival data. The observation were per-
formed from 6 months to 2 years after surgery.
Immunohistochemistry was performed using No-
vocastra® mouse monoclonal antibody antihuman
p53, and Novocastra® Biotinylated Universal se-
condary antibody p53. The positive p53 overex-
pression was determined by brown granule in the
tumor’s cell nucleus. Scoring was performed by
counting the positive cells as follow: score 1 = ≤ 25
%, score 2 = 26 - 50 %, score 3 = 51 - 75 % and
score 4 = 76 - 100 %. Tumor types, tumor differ-
entiation, and expression grade of p53 were deter-
mined by a pathologist. Data were analyzed using
Statistical Program for Social Sciences (SPSS) for
Windows version 11.5.
RESULTS
Samples characterized showed that most of samples
were below 55 years of age (82.9 %), and there
were 8 years and 12 years old among them. Most
histological type was epithelial cancer (80.5 %),
while the rest 19.5 % were non-epithelial types
such as germ cell origin (malignant teratoma, dys-
germinoma), and struma ovarii. The well differen-
tiated cancer was the most frequent (68.3 %), while
31.7 % were poorly differentiated. Patients were
mostly in stage III of disease (48.8 %), followed
by stage I (26.8 %), stage IV (14.6 %), and stage
II (9.8 %).
We found that 58.5 % of samples were overex-
press p53, and most of them was grade 4 (58.3 %),
while grade 1 was 20.8 %, grade 2 was 12.6 %, and
grade 3 was 8.3 %. The epithelial type of ovarian
carcinoma demonstrated higher overexpression of
p53 (63.6 %), while the non-epithelial types show-
ed less or no expression of p53 (62.5 %). Most of
poorly differentiated tumor (92.3 %) showed p53
overexpression, while well differentiated tumor tent
not to show the p53 overexpression (57.1 %). The
p53 overexpression was mostly found in the stage
IV, folowed by stage III, II, and I.
Yate’s correction X2 statistical analysis was applied
to find the relation between p53 overexpression and
histological types and differentiation of ovarian
cancer. We found that the overexpression of p53
has significant relation with histological type of
ovarian cancer (p = 0.0241). Samples that have
positive p53 overexpression were majority epi-
thelial type. We also found that there was signifi-
cant relation between overexpression of p53 and
differentiation of ovarian cancer cells (p = 0.0080).
The poorly differentiated samples have more p53
overexpression.
X2 statistical analysis was applied to find the cor-
relation between p53 overexpresion and ovarian
cancer stage. We found that there was significant
correlation between p53 overexpression with ovar-
ian cancer stage (p = 0.0020). Samples that have
p53 overexpression mostly in advance stages di-
sease (stage III and IV), while samples that were
not expressed p53 more in early stages (stage I and
II).
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The expression of p53 in poorly differentiated
ovarian cancer is shown in figure 1. The p53 pro-
tein was accumulated in the nucleus of tumors and
the expression degrees were increased as his-
topathological grade increased. In this study, we did
not find significant relation between p53 overex-
pression with ages of patients (p > 0.05).
Prognostic value analysis found that there was
significant relation (p = 0.0050) between p53 over-
expression with the outcome of the patients. Those
who have higher p53 overexpression were mostly
died (83.3 %) in the follow-up time compared with
those who have no overexpression of p53 (35.3 %).
The logistic regression analysis found that there
was positive significant relation (p = 0.0130) bet-
ween p53 overexpression with the patients outcome
(OR = 10.5), means that the mortality rate patients
who have p53 overexpression were 10.5 times high-
er than the patients who have no p53 overexpres-
sion.
We also found that the capability of life of ovar-
ian cancer was 12 - 14 months after first diagnosis
established. In the first 5 months after diagnosis,
about 50.0 % patients who have p53 overexpression
were died, while patients without p53 overexpres-
sion 80.0 % still alived. After 8 months, both p53
overexpression patients and no p53 overexpression
have similar cumulative survival (around 20.0 %).
Survival time of p53 overexpression patients were
5.72 months (range 4.09 - 7.35 months), while in
no p53 overexpression patients were 6.74 months
(range 5.16 - 8.31 months).
DISCUSSION
P53 tumor suppressor gene is the most mutated
gene in human cancers. It has been found that 50
% or all human cancer contain p53 mutations10.
However, the role of p53 in ovarian carcinogenesis
is still unclear, although some studies found that
p53 mutant expression could be a prognostic indi-
cator of ovarian cancer patients.
In this study, most samples were above 55 years
old (82.9 %), and there were samples who 8 and
12 years old among them. This data support pre-
vious studies that ovarian cancer incidence is in-
crease with age, and reach the peak at the fifth dec-
ade of life2,3.
The very young age samples showed that the
tend of ovarian cancer express in young age, and
probable of more malignant types and hereditary
factors based on mutation in germ line cells4. This
assumption was supported by our finding, that the
8 years and 12 years old patients have malignant
teratoma, which origin from germ lince cells. Al-
though hereditary ovarian cancer only 5 - 10 % oc-
cur in all ovarian cancer statistically, study of he-
reditary ovarian cancer is very important to be done
in the future especially for genetic councelling pur-
pose.
The most histological type of ovarian cancer in
this study was epithelial type (80.5 %). This finding
support some previous studies that also find similar
results10,11, and this support the hypothesis that ma-
jority of ovarian cancer was originated from the
epithel surface of ovarian cancer. The majority of
our samples was at stage III (48.8 %), and this in-
dicated that patients came to the hospital already
in advance stages. Another reasons are most ovar-
ian cancer has no signs and symptoms and has hide
location, lead to the late diagnosis. However, we
found more well differentiated ovarian cancer grade
(68.3 %), which indicate that clinical stage has less
or no relation to the histopathological differentia-
tion grade.
Immunohistochemistry analysis showed that p53
protein expression is located in cell nucleus. The
accumulated p53 protein was mutant proteins that
have longer half life and more stable than the wild-
type p53. Although normal cell also express p53,
this p53 is not stable and will immediately degraded
and did not or very faint appear using immunohis-
tochemistry technique12.
We found that 58.5 % of samples overexpressed
p53, and there was significant relation between p53
overexpression and clinical stages, histological types,
differentiation grades. P53 overexpression was
Figure 1. Overexpression of p53 in ovarian cancer tissue
(400 x magnifications)
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found more in stage III and IV, more in epithelial
types, and more in poorly differentiated grade.
These results support the statement that p53 gene
play a role in pathogenesis and ovarian cancer pro-
gression. Furthermore, these results also support the
previous studies that p53 overexpression increased
as stage increase and did not found in normal ovarii
and benign ovarii tumor13,14.
It has been known that the relationships among
genotype, phenotype, and clinical manifestation are
very complex. The gene expression has many steps
from the DNA to protein. Some authors found that
neoplastic cell that have p53 missense mutation,
could be observed by immunohistochemistry tech-
nique because this mutation produced stable p53
proteins and longer half-life. They also found that
the frame-shift or nonsense (chain termination/protein
truncated) p53 mutation produced unstable p53 pro-
tein and easily degraded14, and could not be detec-
ted by immunohistochemistry. This might be the
reason why some of our samples did not express
p53. This result needs further study to identify the
type of p53 mutation of our ovarian cancer samples.
The prognosis determination is very important to
increase the quality of life and of patients, such as
determination of the suitable antiresistant chemo-
therapy. Until now, the efficacy of chemotherapy
is limited by resistant capability of tumor to the
chemotherapy. Most ovarian cancer has high res-
pond to level one chemotherapy (initial chemothe-
rapy), but the patients frequently has recurrence
and resistance to the chemotherapy. These make the
prognosis of ovarian cancer is still poor until now,
and the survival rate is still low13,14.
The p53 tumor suppressor gene is the most study
gene for prognosis and prediction of chemotherapy
respond of ovarian cancer patient, but the prognos-
tic value of p53 in ovarian cancer is still contro-
versial. In this study, we found that the most patient
who has high p53 overexpression, died (83.3 %)
compared to patients who has not p53 overexpres-
sion. Statistical analysis demonstrated that the life
capability or ovarian cancer patients was 12 - 14
months after first diagnosis established, and in the
first 5 months around 50 % patients who have high
p53 overexpression were dead. This results support
that p53 gene is an independent marker to poorly
prognosis and is a prognosis indicator of patients
survival.
These results can be used in various clinical ap-
plication of ovarian cancer. If p53 expression of
ovarian cancer tissue patients is high, we can pre-
dict the poorly prognosis because it resistant to che-
motherapy, and the clinician could choose a suit-
able chemoterapy drugs. Furhter study of p53 mu-
tation analysis of ovarian cancer before cisplatin,
doxorubicin, and cyclophosphamide treatment is al-
so needed, because this factor is related to ovarian
cancer chemosensitivity 15,16,17.
This study is still limited in elucidate of patho-
genesis and prognosis of ovarian cancer because
sample number limitation and only analysed one
gene that play the role in carcinogenesis apoptosis.
However, our results could be use as basic data for
further ovarian cancer study.
CONCLUSIONS
1. The p53 overexpression is related to the advance
stages, epithelial type, and poorly differentiated
grade of ovarian cancer.
2. The p53 overexpression has a prognostic value
to the survival rate of ovarian cancer patients.
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